Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2000

01-01-2000

Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin

Authors: Sungki Choi, Masanobu Kobayashi, Jingxin Wang, Hasem Habelhah, Futoshi Okada, Jun-ichi Hamada, Tetsuya Moriuchi, Yasunori Totsuka, Masuo Hosokawa

Published in: Clinical & Experimental Metastasis | Issue 1/2000

Login to get access
Metadata
Title
Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin
Authors
Sungki Choi
Masanobu Kobayashi
Jingxin Wang
Hasem Habelhah
Futoshi Okada
Jun-ichi Hamada
Tetsuya Moriuchi
Yasunori Totsuka
Masuo Hosokawa
Publication date
01-01-2000
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 1/2000
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1026507713080

Other articles of this Issue 1/2000

Clinical & Experimental Metastasis 1/2000 Go to the issue

OriginalPaper

Interaction of tumor cells with vascular endothelia: Role of platelet-activating factor

OriginalPaper

CD44 and β1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins

OriginalPaper

A highly metastatic Lewis lung carcinoma orthotopic green fluorescent protein model

OriginalPaper

A new method for assaying adhesion of cancer cells to the greater omentum and its application for evaluating anti-adhesion activities of chemically synthesized oligosaccharides

OriginalPaper

Isolation and characterization of cell lines with reduced urokinase binding

OriginalPaper

Cyclooxygenase-2 expression in colorectal cancer liver metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits